Abstract In 2010, the American College of Medical Toxicology (ACMT) established its Case Registry, the Toxicology Investigators Consortium (ToxIC). All cases are entered prospectively and include only suspected and confirmed toxic exposures cared for at the bedside by board-certified or boardeligible medical toxicologists at its participating sites. The primary aims of establishing this Registry include the development of a realtime toxico-surveillance system in order to identify and describe current or evolving trends in poisoning and to develop a research tool in toxicology. ToxIC allows for extraction of data from medical records from multiple sites across a national and international network. All cases seen by medical toxicologists at participating institutions were entered into the database. Information characterizing patients entered in 2012 was tabulated and data from the previous years including 2010 and 2011 were included so that cumulative numbers and trends could be described as well. The current report includes data through December 31st, 2012. During 2012, 38 sites with 68 specific institutions contributed a total of 7,269 cases to the Registry. The total number of cases entered into the Registry at the end of 2012 was 17,681. Emergency departments remained the most common source of consultation in 2012, accounting for 61 % of cases. The most common reason for consultation was for pharmaceutical overdose, which occurred in 52 % of patients including intentional (41 %) and unintentional (11 %) exposures. The most common classes of agents were sedative-hypnotics (1,422 entries in 13 % of cases) non-opioid analgesics (1,295 entries in 12 % of cases), opioids (1,086 entries in 10 % of cases) and antidepressants (1,039 entries in 10 % of cases). Nacetylcysteine (NAC) was the most common antidote administered in 2012, as it was in previous years, followed by the opioid antagonist naloxone, sodium bicarbonate, physostigmine and flumazenil. Anti-crotalid Fab fragments were administered in 109 cases or 82 % of cases in which a snake envenomation occurred. There were 57 deaths reported in the Registry in 2012. The most common associated agent alone or in combination was the non-opioid analgesic acetaminophen, being reported in 10 different cases. Other common agents and agent classes involved in death cases included ethanol, opioids, the anti-diabetic agent metformin, sedativeshypnotics and cardiovascular agents, in particular amlodipine. There were significant trends identified during 2012. Abuse of over-the-counter medications such as dextromethorphan remains prevalent. Cases involving dextromethorphan continued to be reported at frequencies higher than other commonly abused drugs including many stimulants, phencyclidine, synthetic cannabinoids and designer amphetamines such as bath salts. And, while cases involving synthetic cannabinoids and psychoactive bath salts remained relatively constant from 2011 to 2012 several designer amphetamines and novel psychoactive substances were first reported in the Registry in
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Medical toxicology
The Toxicology Investigators Consortium (ToxIC) case Registry was established in 2010 by the American College of Medical Toxicology (ACMT) as a prospective toxicosurveillance and research tool. Since all cases on the Registry have had formal consultation by a medical toxicologist they represent particularly severe or potentially severe toxicities. A full description of the Registry has been previously published [1] . Participating sites record all cases cared for at the bedside or in a clinic by medical toxicologists. Previous Annual Reports have been published reflecting the 2010 and 2011 data [2, 3] .
Several enhancements to the main Registry occurred in 2012 including the integration of new focused data collection sub-registries for prospective multi-site studies. The first subregistry was developed for patients who ingest caustics and the second for those who have received lipid resuscitation therapy. Also in 2012, a Steering Committee was created with specific goals such as establishing a data entry and collection quality control and assurance program in order to increase the accuracy and fidelity of data collection. Steering Committee members include the Principle Investigators of the Registry along with several medical toxicologists who have been active in case entry, site recruitment and in surveillance since the Registry's inception. This is the third annual report and it includes both the 2012 experience and comprehensive and comparative data from the first 2 years of the registry (2010-2011). Registry data is described cumulatively for drug classes and for specific drugs and chemicals within each class as well as compared across time in order to demonstrate trends and for the purpose of surveillance. This report also provides data on toxidromes, supportive care and specific treatments provided during the encounter. January  46  442  590  1,078  February  99  505  789  1,393  March  155  775  484  1,414  April  277  617  529  1,423  May  207  323  511  1,041  June  312  501  638  1,451  July  364  684  630  1,678  August  556  573 Table 1 . The information stored on the database includes demographic and detailed clinical data obtained through medical toxicology consultation on the patient's exposure or encounter including signs, symptoms, clinical course, and treatment. For this report, consultation refers to all patient encounters whether admitted to the medical toxicology service on an inpatient unit or when the toxicologist served as consultant. Outpatient and Emergency Department encounters are also referred to as consultations as long as a formal medical toxicology consultation was done and include documentation in the patients' record detailing the consultation.
Information about a patient encounter is collected and subsequently entered into the online data interface. Multiple fields are populated for each patient involving check offs or dropdown boxes. There are free text fields for additional information, such as signaling new, unusual or sentinel cases as well as for entry of the substances or species (i.e., envenomation) involved. A data dictionary was added to the 2012 Registry to facilitate accurate collection and naming of specific substances or drugs.
For this report, a search was made of the database assessing the parameters in each field between the data of January 1, 2012 and December 31, 2012. For comparative purposes, and when such data exists, the 2010, 2011, and 2012 as well as cumulative 2010-2012 data are shown. 2012, 67 % of consultations involved patients 19-65 years old, 26 % involved pediatric patients ages 18 years or less and 6 % involved patients aged >65 years old. Forty-nine percent of the consultations involved female patients in 2012. Table 4 shows the referral source for medical toxicology consultations. As shown in Table 4 , 61 % of consultations came from the emergency department in 2012 and 12 % were transferred from other hospitals to ToxIC sites. In 2012, 41 % of cases were intentional pharmaceutical exposures, which was the most common reason for the encounter in the Registry. Many cases were coded for more than one reason (e.g. "Intentional Exposure-Pharmaceutical" and "Drug Abuse-Prescription"). Intentional exposures for nonpharmaceuticals were the second most common reason for case encounters (12 %) followed by unintentional exposures with pharmaceuticals (11 %). Drug abuse-related case entries remained a common cause of consultation in 2012 with 10 % Table 5 shows the frequency of medical toxicology consultations sorted by the reason a consultation was obtained. Sedative-hypnotics and muscle relaxants with 1,422 exposures (20 % of all 2012 entries) were the most common class of agents responsible for medical toxicology consultation. Clonazepam was the most frequently encountered sedative encountered followed by alprazolam. Sedative-hypnotics and muscle relaxants surpassed non-opioid analgesics (20 %) as the most common class of medications encountered during toxicology consultations in 2012. Exposure rates and Registry entries for different exposure classes are included in Table 6 . Opioids (16 %) and antidepressants (15 %) were the third and fourth most common agents described in medical toxicology consultation in 2012. Table 7 features the major types of toxidromes identified in Registry entries by year. In 2012, specific toxidromes were identified in 22 % of all Registry cases entered. A sedativehypnotic toxidrome was identified in 40 % of the cases identified as having a toxidrome, the anticholinergic toxidromes was identified in 23 %, a sympathomimetic toxidromes in 13 %, an opioid toxidromes in 13 % and serotonin syndrome was described in 10 % of these cases.
Results

Total
During 2012, patient deaths occurred in 57 cases. This is compared to 35 reported deaths in 2011. The 2010 report did not include fatality data. Table 8 further describes the 2012 fatalities by age, gender, and agents reported in consult. Table 9 compares the frequency of specific agents reported for 2011, 2012 and cumulatively. The most common agent identified either as sole drug or in combination with other agents in 2012 deaths, was the non-opioid analgesic acetaminophen which was reported in ten different cases. The next most frequently cited agent in death cases was ethanol with reported as co-ingestant in five reports followed by amlodipine, gabapentin, and metformin in four cases each. Acetaminophen was reported in three cases as isolated agent and in seven cases along with other agents. Non-opioid analgesics were the most common class of drug cited in death cases. Other common classes included opioids (methadone, hydrocodone, heroin, fentanyl, and tramadol) sedatives (including benzodiazepines, and gabapentin) and cardiovascular medications (amlodipine, digoxin, lisinopril, atenolol, metoprolol, and propranolol). Out of the 57 reported cases, 29 cases involved single drugs, 18 included multiple agents and 10 involved unknown agent or agent combinations.
There were six pediatric fatalities with one in the 13-18 years range with unknown agents ingested and another 16-year-old female ingesting propranolol. There were two death cases in the 2-6-year-old age group with unknown agents involved and two cases reported occurring in children less than 2 years of age. One of these was due to accidental morphine ingestion and the other was from unknown agents. The rest of the fatalities were in adults with 7 involving individuals >65 years old and 44 cases occurring in the 19-65 year-old age range. Fifty-four percent (31 of 57) of fatality cases were in women compared to 2011 where females were reported in just one third (14 of 35) of death cases.
In 2012, intentional exposure to pharmaceutical agents was the most common method of exposure associated with death with 25 reports followed by unintentional exposure to pharmaceuticals with 11. Illicit drug abuse was reported twice and prescription drug abuse was reported three times in the fatality cases. Adverse Drug Reactions resulting in death also occurred; in fact, three out of the four metformin deaths were cited due to adverse drug reactions (ADRs).
Sedative-hypnotic and muscle relaxant agents are shown in Table 10 . Agents in these classes involved 13 % of all agents and 20 % of all the cases that were entered into ToxIC in 2012. Benzodiazepines accounted for 54 % of cases in this category. Among the benzodiazepines, the most common was clonazepam, identified in 31 % of all benzodiazepine entries and 17 % of total sedative-hypnotics and muscle relaxants, followed by alprazolam in 26 %, lorazepam in 19 %, and diazepam in 9 % of the benzodiazepine entries for 2012. Zolpidem (8 %) and gabapentin (8 %) were the most common non-benzodiazepine sedative-hypnotic exposure in 2012. Muscle relaxants accounted for 21 % of the cases in this category while within the muscle relaxants group cyclobenzaprine encountered most frequently (45 %) of the muscle relaxants followed by carisoprodol (29 %) and baclofen (18 %). Non-opioid analgesic agents are reported in Table 11 . Acetaminophen was again the most common non-opioid analgesic reported in 2012 reported in 67 % of all non-opioid analgesic agent entries. Acetaminophen was reported in 12 % of all Registry cases in 2012. Salicylates (18 %) and non-salicylate non-steroidal anti-inflammatory agents (NSAIDs) made up the rest of this category (15 %). Ibuprofen was the most common NSAID reported (12 %) followed by naproxen (2 %). Aspirin was responsible for nearly all the salicylate entries again in 2012. Table 12 shows the antidepressant agents. The most frequently encountered antidepressant in 2012 was trazodone (4) 59 (4) 121 (3) Temazepam 17 (2) 34 (2) 27 (2) 78 (2) Midazolam
Subtotal-benzodiazepine agents 489 (58) 876 (54) 770 (54) 2135 (57) Muscle relaxants Cyclobenzaprine 66 (8) 118 (8) 135 (9) 319 (9) Carisoprodol 48 (6) 94 (6) 88 (6) 230 (6) Baclofen 25 (3) 43 (3) 53 (4) 121 (3) Methocarbamol 
Subtotal-barbiturate agents 37 (4) 65 (4) 57 (4) 156 (4) Z-drugs (non-benzodiazepine GABA-a Agonists) Zolpidem 80 (10) 132 (9) 118 (8) 330 (9) % is from the total number in the overall agent class unless otherwise noted in the text (i.e., clonazepam is 31 % of all benzodiazepines but 17 % of the total number of sedative-hypnotics and muscle relaxants included in Table 9 ) (15 %) followed by bupropion (15 %), amitriptyline (12 %) and citalopram (12 %). Selective serotonin reuptake inhibitors (SSRIs) were the most common class of antidepressant reported (34 %) followed by tricyclic antidepressants (TCAs) (18 %) and serotonin-norepinephrine reuptake inhibitors (SNRIs) (13 %). Amitriptyline was the most common of the TCAs and venlafaxine was the most common SNRIs (7 %) in 2012.
Opioids and opiates accounted for 1,086 entries in 2012 (Table 13 ). The most common category was the semisynthetic opioid agents with 55 % of all opioid entries. Oxycodone was the most common semisynthetic opioid reported in 2012 accounting for 40 % of all semisynthetic opioids. Oxycodone was also the most common opioid overall in 2012 reported in 22 % of all opioid agent entries. The synthetics, with methadone, tramadol, and fentanyl topping the list, made up 29 % of the opioid agents in 2012. Methadone was the most common synthetic opioid accounting for 14 % of total opioid agent entries and 46 % of all synthetic opioid entries. Tramadol was reported in 10 % of opioid-related entries. Buprenorphine, the 
Salicylates Acetylsalicylic acid 137 (15) 247 (17) 192 (15) 576 (16) Unspecified/other salicylates 0 (0) 60 (4) 35 (3) 95 (3) Other partial agonist used in the treatment of opioid-dependence (often simply referred to as Suboxone™ which is the most common formulation containing buprenorphine) was reported in just fewer than 5 % of all opioid entries again in 2012. Heroin use remained high in 2012 with 13 % of cases involving opioid agents due to heroin. There were 137 heroin-related entries in 2012 up from 134 in 2011. Table 14 shows the antihistamine and anticholinergic agents with 457 cases involving agents from this class reported in 2012. Diphenhydramine was the most common antihistamines and anticholinergic agents in 2012 (50 %) followed by hydroxyzine (13 %), benztropine (7 %), and promethazine (7 %).
Cardiovascular agents are listed in Tables 15 and 16 . Antihypertensive agents are included in Table 15 and anticoagulant, antiplatelet and antilipid agents are included in Table 16 . The most common categories of cardiovascular agents included the beta blockers (27 %), sympatholytics which were primarily clonidine (19 %), calcium channel antagonists (18 %), cardiac glycosides (9 %) and angiotensin-converting enzyme (ACE) inhibitors (7 %). Propranolol was the most common beta blocker in 2012, accounting for 37 % of all beta blocker entries. Metoprolol (36 %) was reported with nearly the same frequency. The most common sympatholytic was clonidine, which accounted for nearly three quarters (72 %) of the sympatholytic cases. The most common calcium channel antagonist was amlodipine (44 %) followed by diltiazem (27 %) and verapamil (20 %). Digoxin was specified in 98 % of the cardiac glycoside entries and the most common ACE inhibitor reported was lisinopril (87 %). Hydrochlorothiazide was the most common diuretic reported (50 %) followed by furosemide (29 %). Simvastatin was the most common antilipid agent (35 %) and warfarin (67 %) was the most common anticoagulant encountered. Dabigatran was reported in 15 % of anticoagulant entries in 2012. Table 17 shows agents reported as stimulants and sympathomimetics. While there had been a large increase in these agents from 2010 to 2011 the 2012 data remained stable compared to 2011. Amphetamines and stimulant-type attention-deficit hyperactivity disorder (ADHD) disorder type medications as well as designer amphetamines including mephedrone, methylenedioxypyrovalerone (MDPV) and other amphetamines often referred to as "psychoactive bath salts" are included in Table 17 . Cocaine remains the most common stimulant reported in 2012 (32 %) followed by methamphetamine (11 %), amphetamine (11 %), caffeine (10 %), and methylphenidate (8 %). Psychoactive bath salts and designer amphetamines represented 6 % of the stimulant entries with methylenedioxymethylamphetamine (MDMA) being the most common (4 %) followed by mephedrone (2 %). "Other" designer amphetamines and psychoactive bath salts (including unidentified recreational stimulants identified as bath salts) accounted for 6 % of all stimulant cases.
Agents classified as psychoactive drugs are included in Table 18 . In 2012, marijuana and dextromethorphan were both reported in 29 % of the entries with psychoactive agents reported. Synthetic cannabinoid use (i.e., K2 or Spice) remained flat and was reported in 11 % of all cases involving psychoactive agents. While an overall small number LSD cases were reported (18 times in 2012 accounting for 4 % of psychoactive agent entries) this is markedly up from a single entry for LSD in 2011. Phencyclidine was reported in 95 entries (21 %) up from 57 (16 %) the previous year. Table 19 shows the number of cases involving ethanol. Cases involving ethanol increased from 2011 to 2012. Ethanol was reported 850 times in 2012 up from 580 in 2011. Table 20 shows the antipsychotic agent exposures. The atypical antipsychotics were the most common type of antipsychotic reported with 88 % of all antipsychotic entries involving atypical agents. Quetiapine was the most common 
Total ace inhibiting agents 39 (13) 57 (10) 39 ( atypical antipsychotic reported (48 %) followed by risperidone (13 %), olanzapine (11 %), and aripiprazole (9 %). Haloperidol was reported in 6 % of antipsychotic entries. The most common phenothiazine reported was chlorpromazine (3 %). Lithium was listed separately from the antipsychotics and anticonvulsant mood stabilizers in Table 21 . Lithium was reported 133 times in 2012 up from 100 the previous year. Table 22 includes the anticonvulsant and non-antipsychotic mood stabilizing agents (excluding lithium). Valproic acid (28 %) followed by lamotrigine (27 %) were the most common two agents from this class in 2012. Lamotrigine increased accounting for 27 % of reports involving anticonvulsants and non-antipsychotic mood stabilizing agents in 2012 up from 19 % in 2011. Phenytoin was encountered much less frequently in 2012 making up 11 % of entries in 2012 down from 25 % in 2011. Table 23 includes the gastrointestinal (GI) agents. Omeprazole (25 %) followed by ondansetron (18 %) were the two most common GI agents reported in 2012.
Anti-diabetic agents are shown in Table 24 with sulfonylureas (28 %), metformin (28 %), and insulins (19 %) the most frequent types of anti-diabetic agents reported.
Guaifenesin (38 %) followed by albuterol (25 %) were the most common pulmonary agents reported in 2012 described in Table 25 . Endocrine agents are described in Table 26 , chemotherapeutic agents in Table 27 and antibiotics in 
Other bath salt, cathinone, designer stimulant Table 28 . Anesthetic agents including local and general anesthetics are included in Table 29 .
The non-ethanol alcohols including the "toxic" alcohols ethylene glycol and methanol are included in Table 30 . Ethylene glycol was reported in 51 % followed by isopropyl alcohol (26 %), acetone (6 %) and methanol (5 %). Table 31 includes cases involving hydrocarbons. The most common hydrocarbon agents reported were gasoline (11 %) and benzene (11 %). A total of 45 hydrocarbon exposures were reported in 2012. Table 32 shows the number of cases involving metals and metalloids. Lead (22 %) surpassed iron (18 %) as the most common metal type reported in 2012. Mercury (15 %), cobalt (10 %), and chromium (9 %) were common metal and metalloid agents reported in 2012. Table 33 shows the gas, vapors, dust, and irritant agents. Carbon monoxide was the most common reported agent in this class again in 2012 with 80 entries (67 %). Chlorine (6 %) and cyanide exposure (4 %) were the two next most common gas exposures in 2012. Table 34 shows caustic agent entries. Acids made up 26 % of caustic exposures with hydrochloric (3 %) and hydrofluoric (6 %) acids reported in a similar number of case entries. Alkaline substances made up 34 % of caustic exposures and sodium hydroxide (36 %) was the most common alkaline agent reported. Table 35 shows herbals, supplement, and vitamin agents. Table 36 describes plant and fungi exposures.
Envenomation cases make up Table 37 . Snakebites make up the majority of envenomation entries again in 2012. Crotalus species or "rattlesnakes" make up the majority of snake envenomation entries. Rattlesnakes were reported in 43 % of all envenomation cases. Agkistrodon contortrix or "copperhead" snakes were the second most frequently reported species with 20 % of cases from copperhead envenomation in 2012. Loxosceles reclusa or "brown recluse" spiders accounted for 20 cases (10 %) of envenomation and Lactrodectus (4) 21 (3) 10 (2) 44 ( mactans or "black widows" accounted for 15 (8 %). Scorpions accounted for 9 % of envenomations with most scorpion envenomations unspecified in terms of type of scorpion. Table 38 describes agents involved in weapons of mass destruction (WMD), nuclear and biologic chemicals (NBC) and riot agent exposures. Household products not falling into any of the agent classes listed thus far were not included separately in a table as most agents that fell into this category were included as specific products or with generic names. The majority of these agents were soaps, detergents, and cleaning agents.
ADR-related consultations shown in Table 39 . Lithium (7 %) remained the most common agent reported in ADRs followed by digoxin (4 %). There were 102 different specific medications described in Table 39 . Only drugs listed at least twice were included in the ADR table. Table 40 includes information about antidotes used during 2012. N-acetylcysteine (NAC) was the most frequently administered antidote in 2012 making up 30 % of all antidote entries. Naloxone was the second most common antidote used (19 %) followed by sodium bicarbonate (12 %), physostigmine (11 %), and flumazenil (7 %). Table 41 describes antivenom use. CroFab was used 109 times (83 % of antivenom entries) followed by scorpion antivenom (10 %) and spider antivenom (5 %). Other snake antivenoms were used twice (2 %) in 2012. Table 42 includes chelators used by medical toxicologists in 2012. Succimer (DMSA) was reported 18 times (51 %) followed by deferoxamine 6 times (17 %) and British Anti Lewisite (BAL) 5 times (14 %). The other chelators used were ethylenediaminetetraacetic acid (EDTA) (11 %), unithiol (DMPS) (3 %) and penicillamine (3 %). Table 43 shows decontamination treatments utilized in 2012. Activated charcoal topped the list with 280 entries (81 % of decontamination events), followed by whole bowel irrigation with 41 occurrences (14 %) and gastric lavage with 22 occurrences (6 %). Drug and toxin elimination treatments are described in Table 44 . Hemodialysis was reported 126 times (46 %) followed by urinary alkalinization with 61 occurrences (22 %). Multidose activated charcoal (MDAC) was used in 53 cases (19 %) and continuous renal replacement therapy (CVVHD) was reported 35 times (13 %).
Non-pharmacologic support is described in Table 45 . The most common non-pharmacologic support used in 2012 included intravenous fluid resuscitation, reported 1,294 times (67 %), followed by intubation and ventilator management reported 555 times (29 %). Cardiopulmonary resuscitation (CPR) was done in 36 cases.
Benzodiazepines were the most common agents used for pharmacologic support by medical toxicologists with 1,242 cases using these agents in patient care (57 %). Antipsychotics were used in 9 % of cases involving pharmacologic support, vasopressors in 9 % and non-benzodiazepine anticonvulsants in 5 %. Other drugs used in pharmacologic support by medical toxicologists are included in Table 46 . 
addition of a data dictionary to facilitate agent entry and surveillance. Several noteworthy publications were generated from Registry data in 2012 including a report describing important new information on infant and toddler poisonings [4] . Additional work involving toxico-surveillance began in 2012 including preliminary development of a prospective Registry for cases involving prescription opioid abuse. Sedative-hypnotics remained the most common agents reported in 2012. Clonazepam and alprazolam remained at the top of the list. Sedative-hypnotics and muscle relaxants are frequently reported in cases involving prescription abuse and are only secondary to opioid analgesics in this respect. Many of the opioid-related fatalities that occur in the USA also 
Other metals 0 (0) 6 (2) 4 (2) 10 (2) (5) 1 (2) 6 (2) Mineral oil
Methylene chloride 1 (2) 4 (6) 2 (5) 7 (4) 
(elderberry extract) (10) 10 (20) 21 (11) Probiotics
Serenoa repens (saw palmetto)
Whey protein concentrate 
Areca catechu (betel nut)
Unspecified or other plant
Total plants 7 (25) 4 (7) 10 (19) 21 (15) Mushrooms Amanita bisporigera (destroying angel)
Unspecified cyclopeptidecontaining
Unspecified nontoxic involve sedative-hypnotics and muscle relaxants as coingestants. This combination is particularly lethal in that the degree of impairment to respiration and ventilation may be more severe when these agents are taken together. With nearly 1,500 sedative-hypnotic and muscle relaxant entries occurring annually the ToxIC Registry this represents an excellent mode of toxico-surveillance as well as a source for prospective study regarding the role of sedatives in poisonings and prescription drug abuse-related hospitalizations in particular. 2012 data also confirms the ongoing role of over-thecounter agents in medication abuse. Dextromethorphan was one of the most commonly abused psychoactive agents in 2012 with more references than other commonly abused drugs such as amphetamine or methamphetamine. Dextromethorphan was also reported more frequently than synthetic cannabinoids and designer amphetamines including MDMA and psychoactive bath salts in 2012. In 2012, drug abuse was split into multiple different categories in order to better track the role specific medications in these cases. This occurred halfway through the year in 2012. These modifications to the Registry data entry form will allow for better identification and toxico-surveillance regarding drug abuse-related hospitalizations.
Oxycodone was again the most common opioid encountered in patients seen by medical toxicologists in 2012. Opioids were encountered nearly 1,100 times in 2012. The data regarding prescription opioid exposures appears essentially stable with no major increases or decreases involving specific opioids over the past 2 years. Heroin, which had shown an increase from 2010 to 2011, remained a common cause of opioid-related consultation in 2012. With the further attention to prescription opioid abuse by the legal and medical establishments in 2012, many experts believe heroin use will continue to increase in the coming years. The ToxIC Registry is involved in active surveillance regarding prescription and illicit opioid-related abuse and hospitalizations. In 2013, a major sub-Registry study of cases involving misuse of prescription opioids was initiated. While 2011 marked dramatic increases in designer drug-related hospitalizations compared to 2010, broad federal and state legislation introduced in the summer of 2012 appeared to be effective in reducing Emergency Department visits and hospitalization related to these substances. In fact, 2012 data regarding synthetic and designer drugs remained relatively flat compared to 2011 and some of the more common chemicals that had been sold as psychoactive bath salts such as MDPV and mephedrone, saw significant decreases in 2012 Registry data. Overall-stimulant related entries decreased slightly from 761 in 2011 to 692 in 2012 despite more centers entering cases. Cocaine remained the most common stimulant agent reported in 2012 as it was in 2010 and 2011. Psychostimulant use remained relatively constant although certain agents fluctuated in prevalence; amphetamine was reported less frequently while methylphenidate reports doubled in 2012. This data indicates that psychostimulants continue to cause significant morbidity and mortality in the US.
Several new designer drugs were encountered in 2012 with the "N-Bomb" agents (N -benzyl-ortho-methoxy 2C compounds), ultra-potent hallucinogenic amphetamines active in the 200-500 microgram range, newly identified in Registry entries in 2012. 2012 LSD reports increased dramatically and while not analytically confirmed it is thought that several of the LSD related cases were actually NBOME compounds misrepresented as "synthetic LSD".
Whether synthetic cannabinoid and designer amphetamine drug use will show additional evidence of decreasing in 2013 remains to be seen; however, and regardless of this, novel substances continue to be reported regularly and remain a significant cause of morbidity and public health concern with several designer amphetamines in addition to the NBOME compounds being reported for the first time in the Registry in 2012. A real time toxico-surveillance system that can identify hospitalized patients and evolving and concerning trends related to synthetic and designer drug is increasingly important. This area represents an ongoing area of development and toxico-surveillance for the ToxIC Registry.
Limitations
The data reported herein is subject to several important limitations. ToxIC Registry numbers and trends should not be taken as representative of the use of these agents in the general population as the data reflects only those cases cared for at the bedside by medical toxicologists. This makes the sample representative of cases in which significant morbidity was experienced as cases in which patients were not hospitalized or had minimal signs or symptoms of toxicity are most likely underrepresented in the Registry. As a result, the Registry is more of a marker of significant toxicity or morbidity associated with drug and chemical exposures and envenomations than it is of general population exposures. Another limitation is that in most cases the history of exposure is self-reported or comes from third-party sources. Inaccuracies in this aspect of data collection are a limitation in any data set of this type.
Quality assurance has remained an area of intense interest in the Toxicology Investigators Consortium. The ToxIC Steering Committee has developed a strategy to implement a quality assurance program which will introduce an additional degree of monitoring and lead to fewer inaccuracies and more complete case entries. Despite this, there may be some data that is incompletely or inaccurately reported. To this extent, it is most likely outcome data that are incomplete however, as evidenced by the increase in death cases reported in the Registry in 2012. Sites have been reminded to enter complete cases and to modify entries with significant developments after initially entered into the Registry. The possibility of incomplete data reporting should be less likely in subsequent years as the Registry further develops. Starting in 2012, death as an outcome was mandated to be reported to the Registry. 
